Oscotec Inc.

Translating science into medicine
Sign Up
PRESS
FLT3/AXL Inhibitor (A... 2020.06.22  
List of Articles
Date Website Media Pipeline
2018-06-11 Yuhan ups investment in biotechs for immuno-oncology drug push THE INVESTOR Yuhan/Lazertinib
2019-12-12 Yuhan to start phase-3 trial on lung cancer drug Lazertinib KBR (; Korea Biomedical Review) Lazertinib
2007-02-19 Profiles of Four New Stock-Billionaires MBN Oscotec
2016-01-19 Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money Scrip (Informa Pharma Intelligence) SYK-O-703
2018-11-23 Oscotec`s acute leukemia treatment wins orphan drug status from FDA KBR (; Korea Biomedical Review) SKI-G-801
2019-06-25 Oscotec wins exception policy for continued R&D for new drugs KBR (; Korea Biomedical Review) Oscotec
2017-12-11 Oscotec shares rebound on launch of US clinical trial KBR (; Korea Biomedical Review) SKI-G-801
2018-03-14 More than half of Korean biopharma firms view R&D investments as assets. The Korea Herald Industry
2019-12-14 Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC Targeted Oncology Lazertinib
2019-11-04 Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study THE LANCET ONCOLOGY Lazertinib
2018-11-05 Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech BusinessKorea Lazertinib
2020-05-18 Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations BioSpace Lazertinib
Board Pagination Prev 1 2 Next
/ 2
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.